CIPLA LTD vs CORONA REMEDIES LIMITED
A side-by-side comparison of CIPLA LTD (CIPLA) and CORONA REMEDIES LIMITED (CORONA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads CIPLA vs CORONA on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation40
- Profitability22
- Growth02
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
CIPLA takes 4/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
EvenHow efficiently each company turns capital and sales into profit. Higher is better.
Growth
CORONA takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
CIPLA takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
- + ["Company has delivered good profit growth of 23.3% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%", "Company has been maintaining a healthy dividend payout of 29.4%"]
- − ["Stock is trading at 17.0 times its book value", "Company might be capitalizing the interest cost"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.